NCT06330077View on ClinicalTrials.gov

Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 31, 2024

Primary Completion Date

March 31, 2027

Study Completion Date

June 30, 2027

Conditions
Multiple SclerosisRemitting Relapsing Multiple Sclerosis
Interventions
DRUG

Ifenprodil

Treatment administration

DRUG

Placebo

Treatment administration

Trial Locations (2)

69677

Hôpital Neurologique Pierre WERTHEIMER - HCL, Bron

75013

Groupe Hospitalier Pitié Salpêtrière - APHP, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER